BMRN
BioMarin PharmaceuticalCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The bullish read is that BioMarin now has a faster-growing commercial portfolio after the Amicus close, raised 2026 revenue guidance materially, still has multiple near-term Phase 3 catalysts, and retains substantial valuation upside versus the packet’s median target near $89.5.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Amicus integration raises execution risk just as management shifts 2026 revenue and EPS heavily into 2H.
Momentum
35
Value
65
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $58.00 · Bull $72.00 · Bear $44.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $87.83
Why
Momentum35 · Δ7d -24.3
Value65 · Δ7d -0.0
Sentiment46 · Δ7d -2.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
35
26% active weight
Current posture
7d trendSoftening
Δ7d
-24.3
Δ21d
-4.9
Value
65
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.5
Sentiment
46
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.8
Δ21d
-6.3
Why this grade
Composite grade C. Momentum 35.1 / Value 65.3 / Sentiment 46.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$11.43B
Beta
0.26
Shares Out
193.28M
P/E (TTM)
22.1
P/S (TTM)
3.66
P/FCF (TTM)
13.70
Rev YoY
+6.3%
EPS YoY
-43.1%
Gross Margin
+76.3%
Op Margin
+19.9%
Net Debt
-$917.74M
Current Ratio
5.81
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology